The management of upper gastrointestinal symptoms: is endoscopy indicated?

5 Abinanti FR, Marmion BP. Protective or neutralizing antibody in Q fever. Am J Hyg 1957; 66: 173-195. 6 Hoover TA, Culp DW, Vodkin MH, et al. Chromosomal deletions explain phenotypic characteristics of two antigenic variants phase II and RSA14 (crazy) of the Coxiella burnetii Nine Mile strain. Infect Immun 2002; 70: 6726–6733. 7 Denison AM, Massung RF, Thompson HA. Analysis of the O-antigen biosynthesis regions of phase II isolates of Coxiella burnetii. FEMS Microbiol Lett 2007; 267: 102-107. 8 Ormsbee RA, Bell EJ, Lackman DB, Tallent G. The influence of phase on the protective potency of Q fever vaccine. J Immunol 1964; 92: 404-412. 9 Koster FT, Williams JC, Goodwin JS. Cellular immunity in Q fever: modulation of responsiveness by a suppressor T cell-monocyte circuit. J Immunol 1985; 135: 1067-1072. 10 Izzo AA, Marmion BP. Variation in interferon-gamma responses to Coxiella burnetii antigens with lymphocytes from vaccinated or naturally infected subjects. Clin Exp Immunol 1993; 94: 507-515. 11 Derrick EH. A mystery disease invades Brisbane. Records Australian Academy of Science 1972; 2(3): 39-51. 12 Zhang G, Samuel JE. Vaccines against Coxiella infection. Expert Rev Vaccines 2004; 3: 577-584. 13 Tyczka J, Eberling S, Baljer G. Immunization experiments with recombinant Coxiella burnetii proteins in a murine infection model. Ann N Y Acad Sci 2005; 1063: 143-148. 14 Li Q, Niu D, Wen B, et al. Protective immunity against Q fever induced with a recombinant P1 antigen fused with HspB of Coxiella burnetii. Ann N Y Acad Sci 2005; 1063: 130-142. ❏